Close

Materiality

Materiality(material issues)

Mochida Pharmaceutical Group, striving to deliver value as a pharmaceutical company, formulates a basic policy regarding sustainability to contribute to the realization of a sustainable society.
We recognize the issues surrounding sustainability as important management issues and have identified key matters that our group should prioritize in order to enhance sustainable corporate value as material issues.

Identifying Material Issues

Through an assessment focusing on the two aspects, "importance to society" and "importance to the Group," we identified "creation of unique products that meet needs," "stable supply of products with appropriate quality," "maximization of product value," "expansion of human capital" and "thorough compliance" as material issues.

Process of Identifying Material Issues

In 2022, the Group identified material issues through the following process with reference to various principles and guidelines, and we have been working on our initiatives. In May 2025, we plan to review material issues to enhance its alignment with our management plan and set specific KPIs. Moving forward, we will reassess material issues as appropriate in response to changes in society.

[Step1] Identifying issues

Identify a wide range of potential material issues, taking various principles and guidelines such as SDGs, GRI Index and ISO26000, into consideration.

[Step2] Organizing potential material issues

Map the identified issues on two axes: "importance to society" and "importance to the Group" and narrow down the most important matters.

[Step3] Identifying material issues

Identify the Group's material issues through discussions at the meetings of the Board of Directors and the Sustainability Committee.

The Five Material Issues

Among the Group's five material issues, the Group will work on "creation of unique products that meet needs," "stable supply of products with appropriate quality" and "maximization of product value" as material issues in relation to our businesses and on "expansion of human capital" and "thorough compliance" as material issues underpinning the management foundations.

Material issues in relation to our businesses

  • We will continue working on the "creation of unique products to meet needs," perceiving increasingly diverse medical and healthcare needs as a business opportunity and adapting to changes of the business environment.
  • Through the "stable supply of products with appropriate quality" and "maximization of product value," we will contribute to human health and well-being and seek enhancement in our corporate value.

[Material issues in relation to our businesses]

Material issues Vision Main initiatives KPI

FY25‐FY27

MTP(*1) period

Creation of unique products that meet needs Create farsighted and distinctive products to meet diversifying medical and healthcare needs
  • Expanding pilelines
  • Development of new products in biomaterials, oligonucleotide drugs and celluer medicines
Number of new drug introductions
3 items
Number of healthcare product launches 2 series
Number of biomaterial products launches 5 Products
Number of clinical trials for oligonucleotide drugs  1 item
Number of  clinical trials for cellular medicines  2 items
Stable supply of products with appropriate quality Properly implement product quality management and endeavor to maintain a stable supply
  • Strengthening the quality and safety management system for products
  • Conducting risk management related to product supply operations
  • Establishing a stable production system framework over the medium to long term
Number of significant findings from regulatory inspections 0 cases
Number of products recalls 0 cases
Number of outages 0 cases
Maximization of product value Contributing to human health and well-being by maximizing the potential of our products
  • Providing "new value" by continuously bringing new drugs to the market
  • Providing  "unwavering value" through flagship drugs
  • Providing "healthcare economic value" through generic drugs and biosimilars
New drugs:
Net sales of 5 major products
48 billion yen
Flagship drug:
Volume share of EPA formulations
No. 1 in Japan
Flagship drug:
Net sales of obstetrics and gynecology field 
15 billion yen

Biosimilars:
Number of additional products

3 items

Material issues underpinning the management foundations

  • We believe that a major driver underpinning corporate value creation is "human resources" and therefore, we will strive to create company and workplaces where every employee can demonstrate his or her full potential and grow.
  • We are committed to promoting compliance, which is an absolute condition for corporate survival.

[Material issues underpinning the management foundations]

Material issues Vision Main initiatives KPI

FY25‐FY27

MTP(*1) period

Expansion of human capital Developing an internal environment where diverse human resources can play an active role and cultivating human resources who will persevere in taking on difficult and new challenges and drive value creation.
  • Implementation of initiatives to support the advancement of women
  • Improving the workplace environments to increase employee engagement as a foundation for challenge
  • Implementing diverse training programs to enhance the value of human resources
Ratio of female managers
(Mochida Pharmaceutical)
12% or more
Employee engagement score (Disclosure of actual values)
Number of training participants (Disclosure of actual values)
Thorough compliance Seek to increase compliance awareness as an organization
  • Providing compliance training
  • Operating a hotline for whistleblowing and consulting
  • Conducting employee surveys
Number of serious non-compliance incidents(*2) 0 cases
Awareness of hotline 100%

(*1) MTP : Medium-term Management Plan

(*2)Incidents that have a significant impact on the Group's sales and profits or that are considered necessary to be disclosed outside the company

Page top